CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec
April 26 (Reuters) - CG Oncology Inc CGON.O:
CG ONCOLOGY ANNOUNCES BEST-IN-DISEASE DURABILITY DATA IN BOND-003 COHORT C AND PROMISING EARLY SIGNAL IN COHORT P FOR CRETOSTIMOGENE GRENADENOREPVEC AT THE AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING
CG ONCOLOGY INC - CRETOSTIMOGENE MONOTHERAPY SHOWS 42.3% RESPONSE RATE AT 24 MONTHS
CG ONCOLOGY INC - 58.3% PATIENTS SHOW DURABLE RESPONSE AT 24 MONTHS
CG ONCOLOGY INC - 97.3% PATIENTS FREE FROM MIBC PROGRESSION AT 24 MONTHS
CG ONCOLOGY INC - 91.6% RESPONDERS CYSTECTOMY-FREE AT 24 MONTHS
CG ONCOLOGY INC - NO GRADE 3 OR GREATER ADVERSE EVENTS REPORTED
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey






